Compare Novo Nordisk A/S (NVO) vs VanEck Rare Earth/Strategic Metals (REMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs VanEck Rare Earth/Strategic Metals — how do they compare? Novo Nordisk A/S trades at $46.52 (market cap $207.85B), while VanEck Rare Earth/Strategic Metals trades at $77.3. The key difference: Novo Nordisk A/S pays a 3.81% dividend while VanEck Rare Earth/Strategic Metals pays none. Which is the better fit depends on your goals.
| NVO | REMX | |
|---|---|---|
Market Cap | $207.85B | — |
Sector | Health | Sector/Thematic |
52-Week High | $63.98 | $109.53 |
52-Week Low | $35.29 | $56.60 |
Enterprise Value | $222.55B | — |
Dividend Yield | 3.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
REMX (VanEck Rare Earth and Strategic Metals ETF) trades at $77.03, down 1.81% with a bullish technical signal from moving averages but neutral oscillators. The ETF provides exposure to 38 global rare earth companies, though key financial ratios remain undisclosed. Recent news highlights U.S. efforts to secure critical minerals supply chains amid China's export controls, with Energy Fuels expanding domestic production capacity.
Outlook hinges on geopolitical rare earth dynamics and U.S. supply chain independence initiatives. Risks include high volatility (~50% annualized) and China concentration. Analyst sentiment is mixed due to thematic reliance on policy shifts and commodity cycles, warranting caution for conservative investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About VanEck Rare Earth/Strategic Metals
REMX invests in global companies involved in producing, refining, and recycling rare earth and strategic metals. It provides targeted exposure to critical minerals used in high-tech and green energy, with top holdings like Albemarle and Pilbara Minerals.
Read more on REMX →
